XML 39 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Financial Instruments
12 Months Ended
Dec. 31, 2016
Fair Value Disclosures [Abstract]  
Financial Instruments

Note 19—Financial instruments:

The following table summarizes the valuation of our short-term investments and financial instruments by the ASC Topic 820 categories as of December 31, 2015 and 2016:

 

 

 

Fair Value Measurements

 

 

 

Total

 

 

Quoted
Prices in
Active
Markets
(Level 1)

 

 

Significant
Other
Observable
Inputs
(Level 2)

 

 

Significant
Unobservable
Inputs
(Level 3)

 

 

 

(In millions)

 

Asset (liability)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current

 

$

2.0

 

 

$

—  

 

 

$

2.0

 

 

$

 

Noncurrent

 

 

254.9

 

 

 

3.5

 

 

 

1.4

 

 

 

250.0

 

Currency forward contracts

 

 

(1.2

)

 

 

(1.2

)

 

 

—  

 

 

 

—  

 

Interest rate swap

 

 

(3.5

)

 

 

—  

 

 

 

(3.5

)

 

 

—  

 

December 31, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current

 

$

4.4

 

 

$

—  

 

 

$

4.4

 

 

$

 

Noncurrent

 

 

253.5

 

 

 

.6

 

 

 

2.9

 

 

 

250.0

 

Interest rate swap

 

 

(3.1

)

 

 

—  

 

 

 

(3.1

)

 

 

—  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See Note 6 for information on how we determine the fair value of our marketable securities.

Certain of our sales generated by Chemicals Segment’s non-U.S. operations are denominated in U.S. dollars. Our Chemicals Segment periodically uses currency forward contracts to manage a very nominal portion of currency exchange rate risk associated with trade receivables denominated in a currency other than the holder’s functional currency or similar exchange rate risk associated with future sales. Derivatives that we use are primarily currency forward contracts and interest rate swaps.  We have not entered into these contracts for trading or speculative purposes in the past, nor do we currently anticipate entering into such contracts for trading or speculative purposes in the future. Derivatives used to hedge forecasted transactions and specific cash flows associated with financial assets and liabilities denominated in currencies other than the U.S. dollar and which meet the criteria for hedge accounting are designated as cash flow hedges. Consequently, the effective portion of gains and losses is deferred as a component of accumulated other comprehensive income (loss) and is recognized in earnings at the time the hedged item affects earnings. Contracts that do not meet the criteria for hedge accounting are marked-to-market at each balance sheet date with any resulting gain or loss recognized in income currently as part of net currency transactions. The fair value of the currency forward contracts is determined using Level 1 inputs based on the currency spot forward rates quoted by banks or currency dealers.

 

At December 31, 2016, Kronos had no currency forward contracts outstanding. We did not use hedge accounting for any of our contracts to the extent we held such contracts during 2014, 2015 and 2016.

Interest rate swap contract - As part of our interest rate risk management strategy, in August 2015 Kronos entered into a pay-fixed/receive-variable interest rate swap contract with Wells Fargo Bank, N.A. to minimize our exposure to volatility in LIBOR as it relates to our forecasted outstanding variable-rate indebtedness.  Under this interest rate swap, we will pay a fixed rate of 2.016% per annum, payable quarterly, and receive a variable rate of three-month LIBOR (subject to a 1.00% floor), also payable quarterly, in each case based on the notional amount of the swap then outstanding.  The effective date of the swap contract was September 30, 2015.  The notional amount of the swap started at $344.75 million and declines by $875,000 each quarter beginning December 31, 2015, with a final maturity of the swap contract in February 2020.  The notional amount of the swap as of December 31, 2016 was $340.4.  This swap contract has been designated as a cash flow hedge and qualified as an effective hedge at inception under ASC Topic 815.  The effective portion of changes in fair value on this interest rate swap is recorded as a component of other comprehensive income, net of deferred income taxes.  Commencing in the fourth quarter of 2015, as interest expense accrues on LIBOR-based variable rate debt, we classify the amount we pay under the pay-fixed leg of the swap and the amount we receive under the receive-variable leg of the swap as part of interest expense, with the net effect that the amount of interest expense we recognize on our LIBOR-based variable rate debt each quarter, as it relates to the notional amount of the swap outstanding each quarter, to be based on a fixed rate of 2.016% per annum in lieu of the level of LIBOR prevailing during the quarter.  The amount of hedge ineffectiveness, if any, related to the swap will be recorded in earnings (also as part of interest expense).  Since the inception of the swap through December 31, 2016, there have been no gains or losses recognized in earnings in the current period representing hedge ineffectiveness with respect to the interest rate swap.

During 2015 and 2016 the pretax amount recognized in other comprehensive income (loss) related to the interest rate swap contract was a $3.1 million loss (in 2015 the amount was a $4.4 million loss).  During 2015 and 2016 $.9 million and $3.5 million, respectively, was reclassified from accumulated other comprehensive income (loss) into earnings (interest expense).  During the next twelve months the amount of the December 31, 2016 accumulated other comprehensive income balance that is expected to be reclassified to earnings is $3.5 million pre-tax.

The fair value of the interest rate swap contract at December 31, 2016 was a liability of $3.1 million and is reflected in the Consolidated Balance Sheet as part of accounts payable and accrued liabilities of $2.9 million and other noncurrent liabilities of $.2 million (in 2015, we had a $3.5 million liability of which $3.3 million was recognized as part of accounts payable and accrued liabilities and $.2 million recognized as part of other noncurrent liabilities).  See Notes 9 and 10.  The fair value of the interest rate swap was estimated by a third party using inputs that are observable or that can be corroborated by observable market data such as interest rate yield curves, and therefore, is classified within Level 2 of the valuation hierarchy.

The following table presents the financial instruments that are not carried at fair value but which require fair value disclosure as of December 31, 2015 and 2016:

 

 

  

December 31, 2015

 

  

December 31, 2016

 

 

  

Carrying
amount

 

  

Fair
value

 

  

Carrying
amount

 

  

Fair
value

 

 

  

(In millions)

 

Cash, cash equivalents and restricted cash equivalents

  

$

229.1

  

  

$

229.1

  

  

$

191.0

  

  

$

191.0

  

Deferred payment obligation

  

 

8.8

  

  

 

8.8

  

  

 

9.0

  

  

 

9.0

  

Long-term debt (excluding capitalized leases):

  

 

 

 

  

 

 

 

  

 

 

 

  

 

 

 

Kronos term loan

  

$

338.0

  

  

$

309.5

  

  

$

335.9

  

  

$

334.6

  

Snake River Sugar Company fixed rate loans

  

 

250.0

  

  

 

250.0

  

  

 

250.0

  

  

 

250.0

  

WCS fixed rate debt

  

 

65.6

  

  

 

65.6

  

  

 

64.0

  

  

 

64.0

  

Valhi credit facility with Contran

  

 

263.8

  

  

 

263.8

  

  

 

278.9

  

  

 

278.9

  

Tremont promissory note payable

  

 

17.1

  

  

 

17.1

  

  

 

14.5

  

  

 

14.5

  

BMI bank note payable

  

 

9.3

  

  

 

9.4

  

  

 

8.4

  

  

 

8.5

  

LandWell note payable to the City of Henderson

  

 

3.1

  

  

 

3.1

  

  

 

2.9

  

  

 

2.9

  

 

  

 

 

  

  

 

 

  

  

 

 

  

  

 

 

  

At December 31, 2016, the estimated market price of Kronos’ term loan was $983 per $1,000 principal amount. At December 31, 2015, the estimated market price of Kronos’ term loan was $900 per $1,000 principal amount. The fair value of Kronos’ term loan was based on quoted market prices; however, these quoted market prices represent Level 2 inputs because the markets in which the term loan trades were not active. The fair value of our fixed-rate nonrecourse loans from Snake River Sugar Company is based upon the $250 million redemption price of our investment in the Amalgamated Sugar Company LLC, which collateralizes the nonrecourse loans, (this is a Level 3 input). Fair values of variable interest rate notes receivable and debt and other fixed-rate debt are deemed to approximate book value. Due to their near-term maturities, the carrying amounts of accounts receivable and accounts payable are considered equivalent to fair value. See Notes 5 and 9.